FDA Clears $40 Generic HIV Prevention Shot for Overseas Use
U.S. regulators have tentatively approved an inexpensive generic version of lenacapavir, a long-acting injection that prevents HIV. India-based Dr. Reddy’s Laboratories developed the medicine and plans to begin shipping it next month. The expected price is $40 per person annually in eligible countries, comparable to daily prevention pills.
Lenacapavir is administered every six months and offers near-complete protection against HIV. The generic is intended for use in 120 low- and middle-income countries. FDA clearance can help speed approvals by national regulators, though availability may take longer where countries require their own review.
The FDA’s tentative designation reflects that Gilead Sciences’ branded version, sold in the United States as Yeztugo, remains under patent. The brand-name drug was approved last year and has a U.S. list price of $28,218 annually. Gilead says its no-fee licensing deals with six generic producers offer a fast and sustainable way to expand access.
The generic was developed through an agreement involving Wits RHI, Unitaid, and the Clinton Health Access Initiative. Before starting lenacapavir and before each injection, people need an HIV test; resistant HIV has been found when the drug is used by someone with an undiagnosed infection. Advocates say funding and distribution are now needed to reach people who could benefit.
Affordable HIV Prevention Takes a Major Step Forward
A twice-yearly HIV prevention injection is moving closer to people who need it: the FDA has tentatively approved Dr. Reddy’s generic lenacapavir for use in 120 low- and middle-income countries. At $40 per person a year, it is priced comparably to daily prevention pills, but requires far fewer doses.
The drug offers near-complete protection against HIV, and studies among people at high risk found new infections were nearly eliminated. The FDA decision can help other countries move more quickly through their own approval processes. Dr. Reddy’s plans to start shipping next month, though access will depend on national reviews and the resources to deliver the medicine.
The contrast with the U.S. price is stark: Gilead’s patented brand, Yeztugo, costs $28,218 a year at list price. Gilead says its royalty-free licenses with six generic makers provide a fast, sustainable route to access, but the immediate challenge is getting the cheaper product to people who need it. Advocates say funding and distribution must follow the approval.
People must be tested for HIV before treatment and with every injection, because use by someone with an undiagnosed infection has been linked to drug-resistant HIV. The low-cost generic is a milestone, not the end of the work to make prevention available at scale.
FDA’s Generic HIV Shot Approval Tests the Balance Between Access and Patents
The FDA has cleared a generic version of lenacapavir for eligible overseas markets, allowing Dr. Reddy’s Laboratories to prepare a $40-a-year HIV-prevention shot for 120 low- and middle-income countries. The injection is given every six months, and the company plans to begin shipments next month.
The approval is tentative because Gilead Sciences’ branded Yeztugo remains protected by a patent. Gilead’s drug was approved last year and carries a U.S. list price of $28,218 a year. The company says royalty-free agreements with six generic manufacturers represent the quickest sustainable path to broaden access. The new generic is not available for sale in the United States.
The FDA’s clearance is intended to support the quality of medicines supplied to other countries and may help accelerate national approvals. But the drug still requires HIV testing before a person starts and before every injection; resistant HIV has been identified when it is used by someone with an undiagnosed infection. Supply, local review and distribution all matter alongside price.
The generic was developed by Dr. Reddy’s with support from Wits RHI, Unitaid, and the Clinton Health Access Initiative. Advocates say financing and the practical work of reaching millions of people remain ahead. The approval could widen access, but the rollout remains dependent on countries’ regulatory steps and the ability to deliver the medicine.
